Notice of Q2 and Interim Results

Benchmark Holdings PLC

26 April 2024

 

26 April 2024

Benchmark Holdings plc

("Benchmark" or "the Company")

Notice of Q2 and Interim Results

Webcast for analysts and institutional investors

Equity Development webcast for retail investors

Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will announce its Q2 and interim results, for the three and six month periods ended 31 March 2024, on Wednesday, 22 May 2024.

Presentation for analysts and institutional investors at 8.00 UK (9.00 CET)

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a presentation for analysts and institutional investors on the day at 08.00 UK time (9.00 CET).

The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway. To register your interest, please contact [e-mail]

A live webcast of the presentation will be available for analysts and investors to join remotely at the following link: https://channel.royalcast.com/landingpage/hegnarmedia/20240522_1/

Equity Development webcast for retail investors at 12:30pm UK time

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers at 12.30pm UK time. The webcast is open to all existing and potential shareholders.

To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-22may2024

For further information, please contact: Benchmark Holdings plc [e-mail] Trond Williksen, CEO Septima Maguire, CFO Ivonne Cantu, Investor Relations Deutsche Numis (Broker and NOMAD) Tel:  [phone] Freddie Barnfield, Duncan Monteith, Sher Shah MHP Tel:  [phone] Katie Hunt, Reg Hoare [e-mail] Equity Development Hannah Crowe Tel:  [phone]

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

END